LIfT Biosciences

LIfT Biosciences

Innately curing cancer

Year invested

LIfT Biosciences is committed to developing the world's first cell therapy to destroy all solid tumours, irrespective of strain or mutation. They are achieving this by bringing to market a first in class allogeneic innate cell therapy called Neutrophil Only Leukocyte Infusion Therapy (N-LIfT). Their first mission is to show remission in high unmet need solid tumours by 2022, with an initial focus on pancreatic cancer.

Meet the team

More in Deep Tech